Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma1
- 22 August 2006
- journal article
- research article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 17 (6), 458-465
- https://doi.org/10.1111/j.1399-3038.2006.00425.x
Abstract
We aimed to compare the efficacy and safety of budesonide/formoterol (Symbicort) with budesonide alone (Pulmicort) or budesonide (Pulmicort) and formoterol (Oxis) administered via separate inhalers in children with asthma. In a 12 wk, double-blind study, a total of 630 children with asthma (mean age 8 yr [4-11 yr]; mean forced expiratory volume in 1 s (FEV(1)) 92% predicted; mean inhaled corticosteroid dose 454 microg/day) were randomized to: budesonide/formoterol (80/4.5 microg, two inhalations twice daily); a corresponding dose of budesonide alone (100 microg, two inhalations twice daily); or a corresponding dose of budesonide (100 microg, two inhalations twice daily) and formoterol (4.5 microg, two inhalations twice daily) (budesonide + formoterol in separate inhalers). The primary efficacy variable was the change from baseline to treatment (average of the 12-wk treatment period) in morning peak expiratory flow (PEF). Other changes in lung function and asthma symptoms were assessed, as was safety. Budesonide/formoterol significantly improved morning PEF, evening PEF and FEV(1) compared with budesonide (all p < 0.001); there was no significant difference between budesonide/formoterol and budesonide + formoterol in separate inhalers for these variables. All other diary card variables improved from baseline in all treatment groups; there were no significant between-group differences. Adverse-event profiles were similar in all groups; there were no serious asthma-related adverse events in any treatment group. budesonide/formoterol significantly improved lung function in children (aged 4-11 yr) with asthma compared with budesonide alone. Budesonide/formoterol is a safe and effective treatment option for children with asthma.Keywords
This publication has 28 references indexed in Scilit:
- Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experienceAnnals of Allergy, Asthma & Immunology, 2004
- Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthmaCurrent Medical Research and Opinion, 2004
- Effect of long‐acting β2 agonists on exacerbation rates of asthma in childrenPediatric Pulmonology, 2003
- Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trialArchives of Disease in Childhood, 1999
- Importance of training for correct Turbuhaler use in preschool childrenActa Paediatrica, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaThe New England Journal of Medicine, 1997
- Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potencyEuropean Respiratory Journal, 1997
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994
- Influence of inspiratory flow rate upon the effect of a Turbuhaler.Archives of Disease in Childhood, 1990